Personal profile
Headline
PROFESSOR | Medicine, Gastroenterology
Fingerprint
Dive into the research topics where Bruce E. Sands is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A Phase 2 Study of MORF-057, an Oral α4β7 Integrin Inhibitor in Moderately to Severely Active Ulcerative Colitis
Sands, B. E., Schreiber, S., Danese, S., Kierkus, J., Abhyankar, B., Choi, M. Y., Soo, C., Wu, Y., Sun, F., Lee, D., Cui, D., Mangada, M., Singhal, P., Hussain, A., Rogers, B. N., Peyrin-Biroulet, L. & Feagan, B. G., Feb 2026, In: Clinical Gastroenterology and Hepatology. 24, 2, p. 525-534 10 p.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
Bowel Urgency in Crohn’s Disease: Effects of Mirikizumab in a Randomized Controlled Phase 3 Study
Jairath, V., D’Haens, G., Sands, B. E., Travis, S., Chaparro, M., Peyrin-Biroulet, L., Chen, M. H., Dubinsky, M., Ferrante, M., Schreiber, S., McGinnis, K., Vadhariya, A., Appelmans, S., Lin, Z., Yu, G., Protic, M., Moses, R. & Ghosh, S., Feb 2026, In: Clinical Gastroenterology and Hepatology. 24, 2, p. 463-473.e5Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Development and External Validation of an Endoscopic and Histologic Pouchitis Assessment Tool: The Atlantic Pouchitis Index
Sedano, R., Ma, C., Hogan, M., Silverberg, M. S., Zou, G., D’Haens, G. R., Rémillard, J., Shackelton, L. M., McFarlane, S. C., Bojic, B., Bressler, B., Rosenfeld, G., Feakins, R. M., Kirsch, R., Marchal, A., Samaan, M. A., Panaccione, R., Hart, A., Sands, B. E. & Dotan, I. & 3 others, , Feb 2026, In: Clinical Gastroenterology and Hepatology. 24, 2, p. 512-524 13 p.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations -
Efficacy and Safety of Guselkumab for Ulcerative Colitis Through Week 92 of the QUASAR Long-Term Extension Study
Lichtenstein, G. R., Allegretti, J. R., Rubin, D. T., Magro, F., Bressler, B., Panés, J., Afif, W., Samaan, M. A., Ye, B. D., Yarandi, S., Germinaro, M., Shipitofsky, N., Miao, Y., Zhang, H., Dignass, A., Sands, B. E., Hisamatsu, T. & Peyrin-Biroulet, L., 2026, (Accepted/In press) In: American Journal of Gastroenterology.Research output: Contribution to journal › Article › peer-review
-
Efficacy of Etrasimod in Ulcerative Colitis: Analysis of ELEVATE UC 52 and ELEVATE UC 12 by Baseline Endoscopic Severity
Yarur, A. J., Reinisch, W., Chang, S., Gecse, K. B., Green, J., Abbatemarco, A. M., Wu, J., Goetsch, M., Lazin, K., Pradeep, G. & Sands, B. E., Jan 2026, In: Clinical Gastroenterology and Hepatology. 24, 1, p. 210-220.e3Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations
Press/Media
-
Weekly Summary: On Holding AG (NYSE:ONON) accelerates rise: up 13% in 2 weeks; +$2.53 [6.8%]
23/05/26
1 item of Media coverage
Press/Media
-
HMN 2026: How Combination therapy could improve outcomes in the most difficult-to-treat patients with inflammatory bowel disease
Abreu,, M. & Sands, B. E.
22/05/26
1 item of Media coverage
Press/Media
-
Co-antibody combo bests golimumab, guselkumab in refractory IBD
Abreu,, M. & Sands, B. E.
22/05/26
1 item of Media coverage
Press/Media
-
Can Johnson & Johnson (NYSE:JNJ), sustain its upward momentum this Wednesday?
20/05/26
1 item of Media coverage
Press/Media
-
Can Johnson & Johnson (NYSE:JNJ), turn momentum into continued success?
15/05/26
1 item of Media coverage
Press/Media